Mitsubishi Tanabe Incurs Operating Loss for 3 Years Running, Logs Write-Down on OA Drug

Mitsubishi Tanabe Pharma suffered a third consecutive year of operating losses in FY2021, albeit narrower versus the prior year, as the review of its osteoarthritis development program resulted in a write-down of intangible assets, the company said on May 13...read more